PET and functional anatomic fusion imaging in lung and breast cancers

Cancer Journal

Volumn 10, Issue 4, 2004, Pages 251-261

  Görres, Gerhard W ^a,b   Steinert, Hans C ^a,b   Von Schulthess, Gustav K ^a,b  

^a University Hospital ^*

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

18F FDG; Breast cancer; Image fusion; Lung cancer; PET CT

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT PLANNING; WHOLE BODY SCINTISCANNING; BREAST TUMOR; IMAGE PROCESSING; IMAGE QUALITY; LUNG TUMOR; METABOLISM; REVIEW; SCINTISCANNING;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BREAST NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS;

EID: 16644402809     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200407000-00006     Document Type: Article

References (48)

1. Hany TF, Steinert HC, Goerres GW et al. Improvement of diagnostic accuracy of PET imaging using a high performance in-line PET-CT system: preliminary results. Radiology 2002;225:575-581.
2. Steinert HC, von Schulthess GK. Initial experience using a new integrated in-line PET/CT system. Br J Radiol 2002;75:S36-38.
3. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography-computed tomography. N Engl J Med 2003;348:2500-2507.
4. Hellwig D, Ukena D, Paulsen F et al. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren [German]. Pneumologie 2001;55:367-377.
5. Dizendorf EV, Baumert BG, von Schulthess GK et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44:24-29; commentary 30-32.
6. Kernstine KH, McLaughlin KA, Menda Y et al. Can-FDG PET reduce the need for mediastinoscopy in potentially resectable non-small cell lung cancer? Ann Thorac Surg 2002;73:394-402.
7. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-446.
8. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-377.
9. Vansteenkiste JF, Stroobants SG, Dupont PJ et al, and the Leuven Lung Cancer Group. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur J Nucl Med 1998;25:1495-1501.
10. Weder W, Schmid R, Bruchhaus H et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-893.
11. Erasmus JJ, Patz EF, McAdams HP et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-1362.
12. Marom EM, McAdams HP, Erasmus JJ. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-809.
13. Schumacher T, Brink I, Mix M et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483-488.
14. Schneider DB, Clary-Macy C, Challa S et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural MPM. J Thorac Cardiovasc Surg 2000;120:128-133.
15. Tse NY, Hoh CK, Hawkins RA et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
16. Adler LP, Crowe JP, al-Kaisi NK et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
17. Wahl RL. Overview of the current status of PET in breast cancer imaging. J Nucl Med 1998;42:1-7.
18. Bender H, Kirst J, Palmedo H et al. Value of 18 fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687-1692.
19. Crippa F, Seregni E, Agresti R et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-1434.
20. Mankoff DA, Dunnwald LK, Gralow JR et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-509.
21. Eubank WB, Mankoff DA, Schmiedl UP et al. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR Am J Roentgenol 1998;171:1103-1110.
22. Avril N, Dose J, Janicke F et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-1209.
23. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588-1593.
24. Adler LP, Faulhaber PF, Schnur KC et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997;203:323-327.
25. Crippa F, Agresti R, Seregni E et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4-8.
26. Eubank WB, Mankoff DA, Takasugi J et al. 18-fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-3523.
27. Brix G, Henze M, Knopp MV et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 2001;11:2058-2070.
28. Crowe JP Jr, Gordon NH, Antunez AR et al. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991;126:429-432.
29. Goldhirsch A, Gelber RD, Price KN et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343:377-381.
30. van Dongen JA, Voogd AC, Fentiman IS et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-1150.
31. Leborgne F, Leborgne JH, Onega B et al. Breast conservation treatment of early stage breast cancer: patterns of failure. Int J Radiat Oncol Biol Phys 1995;31:765-775.
32. Bagley FH, Walsh JW, Cady B et al. Carcinomatous versus radiation-induced brachial plexus neuropathy in breast cancer. Cancer 1978;41:2154-2157.
33. Orel SG, Schnall MD. MR Imaging of the Breast. Radiology 2001;220:13-30.
34. Mumtaz H, Davidson T, Hall-Craggs MA et al. Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. Br J Surg 1997;84:1147-1151.
35. Friedrich M. MRI of the breast: state of the art. Eur Radiol 1998;8:707-725.
36. Kraemer S, Schulz-Wendtland R, Hagedorn K et al. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res 1998;18:2159-2162.
37. Rieber A, Merkle E, Zeitler H et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997;21:780-784.
38. Gilles R, Guinebretiere JM, Shapeero LG et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993;188:473-478.
39. Dao TH, Rahmouni A, Campana F et al. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993;187:751-755.
40. Schwaibold F, Fowble BL, Solin LJ et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991;21:299-310.
41. Probstfeld MR, O'Connell TX. Treatment of locally recurrent breast carcinoma. Arch Surg 1989;124:1127-1129; discussion 1130.
42. Moon DH, Maddahi J, Silverman DH et al. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-435.
43. Goerres GW, Michel SCA, Fehr MK et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol, in press.
44. Kamel EM, Wyss MT, Fehr MK et al. [18F]-f1uorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin 2003;129:147-153.
45. Hathaway PB, Mankoff DA, Maravilla KR et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807-814.
46. European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. http://www.esmo.org/
47. Ahmad A, Barrington S, Maisey M et al. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79:478-482.
48. Ciernik IF, Dizendorf E, Baumert BG et al. Radiation treatment planning based on an integrated computer-assisted positron emission tomography (PET/CT). Int J Radiat Oncol Biol Phys 2003;57:853-863.